Cargando…

RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress

Due to the COVID-19 infection, which was recognized as a global pandemic by the WHO on March 11, 2020, the number of cases and disease-related deaths increases day by day globally. For this reason, antiviral agents used in treatment and vaccines, the most effective weapon in prevention, continue to...

Descripción completa

Detalles Bibliográficos
Autores principales: RUDVAN AL, Leyla İpek, SÖNMEZER, Meliha Çağla, ÜNAL, Serhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771051/
https://www.ncbi.nlm.nih.gov/pubmed/34365779
http://dx.doi.org/10.3906/sag-2104-139
_version_ 1784635511887888384
author RUDVAN AL, Leyla İpek
SÖNMEZER, Meliha Çağla
ÜNAL, Serhat
author_facet RUDVAN AL, Leyla İpek
SÖNMEZER, Meliha Çağla
ÜNAL, Serhat
author_sort RUDVAN AL, Leyla İpek
collection PubMed
description Due to the COVID-19 infection, which was recognized as a global pandemic by the WHO on March 11, 2020, the number of cases and disease-related deaths increases day by day globally. For this reason, antiviral agents used in treatment and vaccines, the most effective weapon in prevention, continue to be the most popular topic of the plan. Several situations are expected to affect the course of the pandemic. The loss of the ability of the virus to mutate and cause disease, the fact that those who become immunized by having the disease in the society reach a critical rate and create social immunity (herd immunity), and the provision of social immunity with effective vaccination can be counted as some of these situations.Candidate vaccines in the clinical phase among RNA-based vaccines: This review aimed to examine COVID-19 vaccine candidates using RNA technology and compile its current data. We used PubMed, Google Scholar, and World Health Organization (WHO) databases. Also, we followed up on the latest news and developments on vaccine companies’ websites.Conclusion: Vaccination trials, which started due to the seriousness and urgency of the situation that we are in, continue exceptionally quickly and effectively. As per the WHO›s data on July 9, 2021, there have been 291 vaccine trials, 107 of which are in the clinical phase, and 18 (16%) of the vaccine candidates in the clinical phase are RNA-based vaccines. Also, the number of RNA-based vaccines with ongoing preclinical trials is 2
format Online
Article
Text
id pubmed-8771051
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Scientific and Technological Research Council of Turkey
record_format MEDLINE/PubMed
spelling pubmed-87710512022-02-01 RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress RUDVAN AL, Leyla İpek SÖNMEZER, Meliha Çağla ÜNAL, Serhat Turk J Med Sci Article Due to the COVID-19 infection, which was recognized as a global pandemic by the WHO on March 11, 2020, the number of cases and disease-related deaths increases day by day globally. For this reason, antiviral agents used in treatment and vaccines, the most effective weapon in prevention, continue to be the most popular topic of the plan. Several situations are expected to affect the course of the pandemic. The loss of the ability of the virus to mutate and cause disease, the fact that those who become immunized by having the disease in the society reach a critical rate and create social immunity (herd immunity), and the provision of social immunity with effective vaccination can be counted as some of these situations.Candidate vaccines in the clinical phase among RNA-based vaccines: This review aimed to examine COVID-19 vaccine candidates using RNA technology and compile its current data. We used PubMed, Google Scholar, and World Health Organization (WHO) databases. Also, we followed up on the latest news and developments on vaccine companies’ websites.Conclusion: Vaccination trials, which started due to the seriousness and urgency of the situation that we are in, continue exceptionally quickly and effectively. As per the WHO›s data on July 9, 2021, there have been 291 vaccine trials, 107 of which are in the clinical phase, and 18 (16%) of the vaccine candidates in the clinical phase are RNA-based vaccines. Also, the number of RNA-based vaccines with ongoing preclinical trials is 2 The Scientific and Technological Research Council of Turkey 2021-12-17 /pmc/articles/PMC8771051/ /pubmed/34365779 http://dx.doi.org/10.3906/sag-2104-139 Text en Copyright © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Article
RUDVAN AL, Leyla İpek
SÖNMEZER, Meliha Çağla
ÜNAL, Serhat
RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress
title RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress
title_full RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress
title_fullStr RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress
title_full_unstemmed RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress
title_short RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress
title_sort rna-based covid-19 vaccine candidates with clinical phase trials in progress
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771051/
https://www.ncbi.nlm.nih.gov/pubmed/34365779
http://dx.doi.org/10.3906/sag-2104-139
work_keys_str_mv AT rudvanalleylaipek rnabasedcovid19vaccinecandidateswithclinicalphasetrialsinprogress
AT sonmezermelihacagla rnabasedcovid19vaccinecandidateswithclinicalphasetrialsinprogress
AT unalserhat rnabasedcovid19vaccinecandidateswithclinicalphasetrialsinprogress